Skip to main content

Advertisement

SpringerLink
Log in

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma

Serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In order to study the relation to the metastatic profile and survival, we evaluated the association between pretreatment serum levels of IL-6, TNF-alpha, and erythropoietin (EPO) and metastatic distribution and survival in 16 patients with metastatic malignant melanoma. IL-6 and TNF-alpha immunoassay (R&D Systems, Inc. Minneapolis, USA) employs the quantitative sandwich enzyme immunoassay technique. The Quantikine IVD EPO ELISA (R&D Systems, Inc.) is based on the double-antibody sandwich method. The baseline serum IL-6 and EPO levels were significantly higher in patients with metastatic malignant melanoma than in the control group (p=0.009 and p=0.033, respectively). Serum IL-6 levels were higher in patients with weight loss (p=0.02), who were anemic (p=0.026), with elevated serum LDH levels (p=0.028), and who were chemotherapy nonresponding (p=0.016). The relationship of serum IL-6 concentration to the tumor burden was not determined. Only serum EPO level was influenced by hemoglobin status (p=0.001). No difference was shown among these three parameters. Elevated serum IL-6 concentration (p=0.002) was found to be an adverse prognostic factor in patients with poor performance status, weight loss, low serum hemoglobin, elevated serum LDH, and unresponsive to chemotherapy. On the other hand, both serum TNF-alpha and EPO levels were of no prognostic value. Serum levels of IL-6 were found to be prognostic factors as valuable as serum LDH levels in patients with metastatic malignant melanoma. Their prognostic value should be further evaluated in a larger patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balch CM, et al. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 5th ed. Lippincot Raven, Philadelphia: 1997.

    Google Scholar 

  2. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000; 18: 3782–3793.

    PubMed  CAS  Google Scholar 

  3. Presant CA, Bartolucci AA. Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group experience. Cancer 1982; 49: 2192–2196.

    Article  PubMed  CAS  Google Scholar 

  4. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995–3005.

    Article  PubMed  CAS  Google Scholar 

  5. Sirott MN, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993; 72: 3091–3098.

    Article  PubMed  CAS  Google Scholar 

  6. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193–201.

    PubMed  CAS  Google Scholar 

  7. Brand CU, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma: an analysis of related prognostic factors. Cancer 1997; 79: 2345–2353.

    Article  PubMed  CAS  Google Scholar 

  8. Falkson CI, Falkson HC. Prognostic factors in metastatic malignant melanoma. Oncology 1998; 55: 59–64.

    Article  PubMed  CAS  Google Scholar 

  9. Eton O, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103–1111.

    PubMed  CAS  Google Scholar 

  10. Keilholz U, Martus P, Punt CJ. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38: 1501–1511.

    Article  PubMed  CAS  Google Scholar 

  11. Balch CM, et al. A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126–134.

    PubMed  CAS  Google Scholar 

  12. Moretti S, et al. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001; 11: 395–399.

    Article  PubMed  CAS  Google Scholar 

  13. Deichmann M, et al. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000; 19: 301–307.

    PubMed  CAS  Google Scholar 

  14. Vuoristo MS, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res 2000; 10: 237–241.

    PubMed  CAS  Google Scholar 

  15. Mauawad R, et al. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999; 9: 181–188.

    Article  Google Scholar 

  16. Mouawad R, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2: 1405–1409.

    PubMed  CAS  Google Scholar 

  17. Mouawad R, Antoine EC, Khayat D, Soubrane C. Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients. Cytokines Cell Mol Ther 2000; 6: 135–140.

    PubMed  CAS  Google Scholar 

  18. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7: 151–156.

    Article  PubMed  CAS  Google Scholar 

  19. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565, 573.

    Article  PubMed  CAS  Google Scholar 

  20. Ocvirk J, Stabuc B, Rudolf Z, Galvani V, Curin-Serbec V. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients. Melanoma Res 2000; 10: 253–258.

    Article  PubMed  CAS  Google Scholar 

  21. Cubillos S, Scallon B, Feldmann M, Taylor P. Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model. Anticancer Res. 1997; 17: 2207–2211.

    PubMed  CAS  Google Scholar 

  22. Kettelhack C, Schoter D, Matthias D, Schlag PM. Serum erythropoietin levels in patients with solid tumours. Eur J Cancer 1994; 30A: 1289–1291.

    Article  PubMed  CAS  Google Scholar 

  23. Yasuda Y, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021–1029.

    Article  PubMed  CAS  Google Scholar 

  24. Selzer E, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000; 10: 421–426.

    Article  PubMed  CAS  Google Scholar 

  25. Brouckaert P, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil ®) correlates with altered Doxil ® pharmacokinetics. Int J Cancer 2004; 109: 442–448.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Oncology, Istanbul University, Istanbul, Turkey

    Faruk Tas MD, Hilal Oguz PhD, Andaç Argon MD, Derya Duranyildiz PhD, Hakan Camlica MD, Vildan Yasasever PhD & Erkan Topuz MD

Authors
  1. Faruk Tas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilal Oguz PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andaç Argon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Derya Duranyildiz PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hakan Camlica MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vildan Yasasever PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erkan Topuz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faruk Tas MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tas, F., Oguz, H., Argon, A. et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma. Med Oncol 22, 241–246 (2005). https://doi.org/10.1385/MO:22:3:241

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:3:241

Key Words

Search

Navigation